Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14604202 | 0.98 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL28594000 | 0.84 | TAAR1 (0.33) | CYP3A4TDP1 | |
| SCHEMBL150139 | 0.81 | TDP1 (0.69) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL8073956 | 0.78 | CYP3A4 (0.65) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL4146230 | 0.78 | CYP3A4 (0.65) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL29593649 | 0.74 | CYP3A4 (0.58) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL1120987 | 0.74 | CYP3A4 (0.58) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL18573342 | 0.73 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL4392281 | 0.73 | CYP3A4 (0.65) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL31059891 | 0.72 | CYP3A4 (0.55) | CYP3A4TDP1ESR1ESR2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103797020-B | P-chirality source organic phosphorus compound | 国家科学研究中心 | 2018-01-30 | — | — | CN | disclosed |
| EP-3150613-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-04-05 | — | — | EP | disclosed |
| US-7009065-B2 | Ferrocenyl ligands and the use thereof in catalysis | DEGUSSA AG (DE) | 2006-03-07 | — | — | US | disclosed |
| US-20050234253-A1 | Ferrocenyl ligands and the use thereof in catalysis | DEGUSSA AG (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234253-A1 | Ferrocenyl ligands and the use thereof in catalysis | FECH, SLC40A1, FDPS | CYP3A4 272/4885TDP1 2289/4885ESR1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.